Payment overview · 2025
General Payments
$106.89
6 reported records · 5 companies
Healthcare provider profile · identity verified
Shawn L. Reed, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MOUNT VERNON, OH · NPI 1104894401
Verified facts
What the public records show
CMS Open Payments records show Shawn L. Reed, M.D. received $106.89 in general payments during 2025 across 6 reported records.
Abbott Laboratories accounted for 33.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 148 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 189 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $35.34 | 33.1% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $23.26 | 21.8% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $19.32 | 18.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.22 | 14.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.75 | 12.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $106.89 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $35.34 | 2 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $23.26 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $19.32 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.22 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.22 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 189 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
148 | 34 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
189 | 32 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 468 | 131 |
| Omeprazole | Omeprazole | 418 | 98 |
| Levothyroxine Sodium | Levothyroxine Sodium | 360 | 83 |
| Amlodipine Besylate | Amlodipine Besylate | 306 | 83 |
| Gabapentin | Gabapentin | 304 | 64 |
| Metoprolol Succinate | Metoprolol Succinate | 299 | 74 |
| Pantoprazole Sodium | Pantoprazole Sodium | 292 | 73 |
| Lisinopril | Lisinopril | 259 | 71 |
| Montelukast Sodium | Montelukast Sodium | 225 | 45 |
| Metformin Hcl | Metformin Hcl | 216 | 51 |
| Losartan Potassium | Losartan Potassium | 213 | 62 |
| Meloxicam | Meloxicam | 211 | 51 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 195 | 53 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 189 | 32 |
| Furosemide | Furosemide | 177 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 176 | 49 |
| Duloxetine Hcl | Duloxetine Hcl | 166 | 36 |
| Potassium Chloride | Potassium Chloride | 163 | 38 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 153 | 45 |
| Eliquis | Apixaban | 148 | 34 |
| Methylprednisolone | Methylprednisolone | 143 | 106 |
| Clopidogrel | Clopidogrel Bisulfate | 140 | 34 |
| Simvastatin | Simvastatin | 137 | 30 |
| Trazodone Hcl | Trazodone Hcl | 137 | 30 |
| Sertraline Hcl | Sertraline Hcl | 133 | 31 |
| Glimepiride | Glimepiride | 131 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 125 | 42 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 114 | 27 |
| Ozempic | Semaglutide | 114 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 109 | 26 |
| Pioglitazone Hcl | Pioglitazone Hcl | 107 | 29 |
| Metformin Hcl Er | Metformin Hcl | 101 | 28 |
| Carvedilol | Carvedilol | 92 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 82 | 26 |
| Azithromycin | Azithromycin | 81 | 53 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 81 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 80 | 14 |
| Spironolactone | Spironolactone | 79 | 20 |
| Allopurinol | Allopurinol | 76 | 17 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 76 | 63 |
| Tizanidine Hcl | Tizanidine Hcl | 71 | 14 |
| Tramadol Hcl | Tramadol Hcl | 71 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 69 | 22 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 68 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 67 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 65 | 16 |
| Alprazolam | Alprazolam | 62 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 59 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 58 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 58 | suppressed |
| Aripiprazole | Aripiprazole | 55 | 11 |
| Ezetimibe | Ezetimibe | 55 | 13 |
| Propranolol Hcl Er | Propranolol Hcl | 55 | suppressed |
| Glipizide | Glipizide | 54 | 13 |
| Levofloxacin | Levofloxacin | 53 | 49 |
| Bupropion Xl | Bupropion Hcl | 52 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 49 | 19 |
| Ventolin Hfa | Albuterol Sulfate | 49 | 15 |
| Ondansetron Odt | Ondansetron | 48 | 21 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 47 | 12 |
| Mirtazapine | Mirtazapine | 46 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 46 | 12 |
| Celecoxib | Celecoxib | 44 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | suppressed |
| Famotidine | Famotidine | 43 | 13 |
| Glipizide Er | Glipizide | 43 | suppressed |
| Valsartan | Valsartan | 43 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 42 | suppressed |
| Clonazepam | Clonazepam | 40 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 40 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 39 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 37 | suppressed |
| Jardiance | Empagliflozin | 37 | suppressed |
| Prednisone | Prednisone | 36 | 11 |
| Donepezil Hcl | Donepezil Hcl | 35 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 35 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 34 | suppressed |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 33 | suppressed |
| Trulicity | Dulaglutide | 32 | suppressed |
| Digoxin | Digoxin | 31 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 31 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 31 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | suppressed |
| Finasteride | Finasteride | 30 | 11 |
| Linzess | Linaclotide | 30 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 30 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 29 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 27 | suppressed |
| Fluconazole | Fluconazole | 27 | 15 |
| Ranolazine Er | Ranolazine | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 16 |
| Cephalexin | Cephalexin | 26 | 24 |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 16 |
| Pregabalin | Pregabalin | 22 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 21 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Metolazone | Metolazone | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 16 | suppressed |
| Vraylar | Cariprazine Hcl | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Cartia Xt | Diltiazem Hcl | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Cefdinir | Cefdinir | 13 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Glyburide | Glyburide | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Movantik | Naloxegol Oxalate | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $106.89 · 6 records | Abbott Laboratories | AIRSUPRA, AREXVY, CAMZYOS, FREESTYLE LIBRE 3, LEQVIO, TRELEGY ELLIPTA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error